Announcements Trials
Browse Landscape

Phase

Phase 2 14Phase NA 9Phase 3 5Phase 1/2 5Phase 1 5Phase EARLY_PHASE1 3

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3Other hematologic neoplasm 1

Conditions

Breast Neoplasms 39Glioblastoma 37Glioma 33Prostatic Neoplasms 32Neoplasms 28Multiple Myeloma 26Pancreatic Neoplasms 25Brain Neoplasms 23Colorectal Neoplasms 19Recurrence 18Squamous Cell Carcinoma of Head and Neck 16Melanoma 15Lung Neoplasms 15Neoplasm Metastasis 14Lymphoma, B-Cell 13Lymphoma 13Carcinoma, Non-Small-Cell Lung 13Triple Negative Breast Neoplasms 12Sarcoma 12Leukemia, Myeloid, Acute 12Hematologic Neoplasms 12Head and Neck Neoplasms 12Advanced Solid Tumors 10Stomach Neoplasms 9Ovarian Neoplasms 9Skin Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Neuroblastoma 8Lymphoma, Non-Hodgkin 8Colonic Neoplasms 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Immunoglobulin Light-chain Amyloidosis × 1 year × Clear all
NCT07626476 2026-06-04

Autologous BCMA-targeted CAR-T Cell Injection for Relapsed/Refractory Light Chain Amyloidosis

Beijing Boren Hospital

Phase EARLY_PHASE1 Recruiting
30 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Recurrence

NCT07615270 2026-05-29

A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement

Stanford University

Phase EARLY_PHASE1 Not yet recruiting
5 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT07085559 2025-07-25

Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research

Anhui Provincial Hospital

Phase EARLY_PHASE1 Recruiting
36 enrolled
Other hematologic neoplasmPlasma cell

Immunoglobulin Light-chain Amyloidosis, Leukemia, Plasma Cell, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡